Serum Calprotectin Levels in Vitiligo Patients and Disease Relation

Serum Calprotectin Levels in Vitiligo Patients and Disease Relation

Authors

  • Tugba Atak Ministry of Health Islahiye State Hospital, Dermatology Clinic, Gaziantep, Turkey
  • Selda Pelin Kartal Etlik City Hospital, Dermatology Clinic, Ankara, Turkey
  • Elif Bengu Gungor University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Biochemistry Clinic, Ankara, Turkey
  • Fatma Ucar University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Biochemistry Clinic, Ankara, Turkey

Keywords:

vitiligo, calprotectin, S100A8/A9 protein, oxidative stress, etiology

Abstract

Introduction: Vitiligo is characterized as melanocytes loss in skin and mucous membranes, the pathogenesis of which isn’t yet clarified. Calprotectin is a protein secreted from neutrophils, monocytes, and dendritic cells, which has an effect on cytokine receptor regulation and the production of reactive oxygen radicals. It has been the subject of research in various inflammatory and autoimmune diseases, yet not investigated in vitiligo.

Objective: The aim of our study was to investigate the role of calprotectin in the etiopathogenesis of vitiligo and its relationship with clinical subtypes and disease scores.

Methods: 44 vitiligo patients with lack of autoimmune disease and 36 age and sex matched healthy controls were involved in the study. Serum calprotectin levels were measured by ELISA. The results were compared with the control group, and the relationship between patients' demographic characteristics, skin phototypes, disease type, disease scores (Vitiligo Area Scoring Index and Vitiligo Disease Activity Score), disease duration, and age at onset were evaluated.

Results: The median serum calprotectin level was 454.08 pg/ml (41.19-873.41) in the patient group, and the median serum calprotectin level was 223.17 pg/ml (44.88-1044.43) in the control group. Serum calprotectin level was significantly higher in the patient group than in the control group (p=0.016). No correlation was found between serum calprotectin level and disease scores, disease duration, age, age of onset of disease (p˃0.05).

References

Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473-91.

Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-92.

Hilde Lapeere BB, Sofie De Schepper, Evelien Verhaeghe, Mireille Van Gele, Katia Ongenae, Nanja Van Geel, Jo Lambert, & Lieve Brochez. Hypomelanoses and Hypermelanoses. Fitzpatrick’s Dermatology in General Medicine. 8 ed2012. p. 804-26.

Ortonne TPaJ-P. Vitiligo and Other Disorders of Hypopigmentation. In: Jean L. Bolognia JVS, Lorenzo Cerroni, editor. Dermatology. 4 ed2018. p. 1087-114.

Marchioro HZ, Silva de Castro CC, Fava VM, Sakiyama PH, Dellatorre G, Miot HA. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022;97(4):478-90.

Liu B, Xie Y, Wu Z. Identification of Candidate Genes and Pathways in Nonsegmental Vitiligo Using Integrated Bioinformatics Methods. Dermatology. 2021;237(3):464-72.

Stríz I, Trebichavský I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53(3):245-53.

Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021;70(10):1978-88.

Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020;22(1):105.

He K, Wu W, Wang X, Dai W, Wang S, Li C, et al. Circulatory levels of alarmins in patients with non-segmental vitiligo: Potential biomarkers for disease diagnosis and activity/severity assessment. Front Immunol. 2022;13:1069196.

Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677-83.

Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135(4):407-13.

Alghamdi KM, Kumar A, Taïeb A, Ezzedine K. Assessment methods for the evaluation of vitiligo. J Eur Acad Dermatol Venereol. 2012;26(12):1463-71.

Savas Guzel GE, Mustafa Kulac, Eda Celik Guzel, Volkan Kucukyalcin, Sule Kaya, Ali Riza Kiziler. Chemerin and calprotectin levels correlate with disease activity and inflammation markers in psoriasis vulgaris. Dermatologica Sinica. 2015;33(1):1-4.

Akbarzadeh R, Yu X, Vogl T, Ludwig RJ, Schmidt E, Zillikens D, et al. Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid. J Dermatol Sci. 2016;81(3):165-72.

Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16(6):713-7.

Petersen B, Wolf M, Austermann J, van Lent P, Foell D, Ahlmann M, et al. The alarmin Mrp8/14 as regulator of the adaptive immune response during allergic contact dermatitis. Embo j. 2013;32(1):100-11.

Stascheit F, Hotter B, Hoffmann S, Kohler S, Lehnerer S, Sputtek A, et al. Calprotectin as potential novel biomarker in myasthenia gravis. J Transl Autoimmun. 2021;4:100111.

Badran AY, Gomaa AS, El-Mahdy RI, El Zohne RA, Kamal DT, Abou-Taleb DAE. Serum level of S100B in vitiligo patients: Is it a marker of disease activity? Australas J Dermatol. 2021;62(1):e67-e72.

Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, et al. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021;22(2):797.

Downloads

Published

2024-07-31

How to Cite

1.
Serum Calprotectin Levels in Vitiligo Patients and Disease Relation. Dermatol Pract Concept [Internet]. 2024 Jul. 31 [cited 2024 Dec. 5];14(3):e2024184. Available from: https://www.dpcj.org/index.php/dpc/article/view/4183

Share